IMM.L Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 09:34):
Our systems believe the stock currently is undervalued by 0.25% compare to its pairs and should correct upwards.

Stats
Tagesvolumen	246 505
Durchschnittsvolumen	1.51M
Marktkapitalisierung	8.56M
EPS	£-0.00250 ( Q2 \| 2023-06-30 )
Nächstes Ertragsdatum	( £0 ) 2024-08-28
Last Dividend	£1.000 ( 2021-12-14 )
Next Dividend	£0 ( N/A )
P/E	-2.06 (Sector) 0 (Industry) 0
ATR14	£0.0560 (2.72%)

AMYT.L -11.73%

APH.L -0.13%

AVCT.L -0.33%

AZN.L -0.40%

BMK.L 7.59%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -2.51%

DPH.L 0.05%

EAH.L 3.40%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 3.03%

GNS.L 1.43%

GSK.L -0.50%

HCM.L -0.36%

HEMO.L -2.66%

HIK.L -0.48%

IMM.L -1.15%

INDV.L -0.05%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -2.22%

OXB.L 2.87%

PRM.L -4.82%

PRTC.L 0.98%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 7.87%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 3.48%

STX.L 2.70%

TILS.L 8.33%

TRX.L -1.15%

VAL.L 0.00%

VEC.L 0.00%

Korrelation (AI algo v.1.1b): Undervalued: 0.25% £2.07 paired level. (Der Algorithmus verfolgt in Echtzeit die Änderungen der am stärksten korrelierten Aktien und gibt eine sofortige Aktualisierung)

ImmuPharma PLC Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

ImmuPharma PLC Finanzdaten

Annual	2023
Umsatz:	£0
Bruttogewinn:	£-37 607.00 (0.00 %)
EPS:	£-0.00810

FY	2023
Umsatz:	£0
Bruttogewinn:	£-37 607.00 (0.00 %)
EPS:	£-0.00810

FY	2022
Umsatz:	£0
Bruttogewinn:	£-117 563 (0.00 %)
EPS:	£-0.0126

FY	2021
Umsatz:	£118 350
Bruttogewinn:	£0.00 (0.00 %)
EPS:	£-0.0325

Financial Reports:

No articles found.

ImmuPharma PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

ImmuPharma PLC Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	£1.000	2021-12-14
Last Dividend	£1.000	2021-12-14
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	£1.000	--
Avg. Dividend % Per Year	0.80%	--
Score	0.33	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-07-01)

£0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.33

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2021	£1.000	8.00%
2022	£0	0.00%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
14 Dec 2021	£1.000	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
DNA2.L	Dividend Royal	2024-04-18	Quarterly	9	16.51%	8.69
FAIR.L	Dividend Royal	2024-05-30	Quarterly	9	10.77%	8.67
MPLS.L	Dividend Royal	2024-04-11	Quarterly	7	12.84%	8.67
BGLF.L	Dividend Royal	2024-05-02	Quarterly	9	10.03%	8.50
SEPL.L	Dividend Royal	2024-05-30	Quarterly	11	10.34%	8.34
DNA3.L	Dividend Royal	2024-04-18	Quarterly	12	14.16%	8.31
DEC.L	Dividend Royal	2024-08-29	Quarterly	8	59.83%	7.91
AA4.L	Dividend Royal	2024-04-11	Quarterly	9	12.37%	7.88
IMB.L	Dividend Royal	2024-08-22	Quarterly	28	7.10%	7.51
FBH.L	Dividend Royal	2024-05-02	Annually	22	11.26%	7.46

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-32.54	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-1.255	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-1.936	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.807	0.800	-0.967	-0.773	[1 - 3]
quickRatioTTM	0.125	0.800	-3.97	-3.18	[0.8 - 2.5]
cashRatioTTM	0.125	1.500	-0.416	-0.623	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-2.58	1.000	-2.07	-2.07	[3 - 30]
operatingCashFlowPerShareTTM	-0.00502	2.00	-0.00167	-0.00334	[0 - 30]
freeCashFlowPerShareTTM	-0.00533	2.00	-0.00267	-0.00533	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	-0.326	1.000	-8.76	-8.76	[0.2 - 0.8]
operatingProfitMarginTTM	-31.51	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.0386	0.800	-3.08	-2.46	[0.5 - 2]
Total Score				-6.30

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.03	1.000	-0.306	0	[1 - 100]
returnOnEquityTTM	-1.936	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.00533	2.00	-0.00178	-0.00533	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.00502	2.00	-0.00167	-0.00334	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.822	1.500	-8.82	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-15.93	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-3.03

ImmuPharma PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ImmuPharma PLC

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.